Verified Nov 2026
Chassis & Safety Systems
·

Chantilly, Virginia
·
Since 2014
Granules Pharmaceuticals, Inc. is a U.S. subsidiary of Granules India Limited, headquartered in Chantilly, Virginia, and founded in 2014. The company employs 500–1,000 people and generates an estimated $100–250 million in annual revenue. It manufactures complex oral solid dosage forms including tablets, capsules, powders, and oral solutions for pharmaceutical clients. The firm received FDA Establishment Inspection Report clearance for its Chantilly facility in 2026 and holds DEA approval for controlled substance handling.
Granules Pharmaceuticals, Inc. at a glance
Revenue
$100-250M
Est. band
Employees
500-1,000
Founded
2014
Headquarters
Chantilly, Virginia
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Overview
Granules Pharmaceuticals, Inc. is a U.S. subsidiary of Granules India Limited, headquartered in Chantilly, Virginia, and founded in 2014. The company employs 500–1,000 people and generates an estimated $100–250 million in annual revenue. It manufactures complex oral solid dosage forms including tablets, capsules, powders, and oral solutions for pharmaceutical clients. The firm received FDA Establishment Inspection Report clearance for its Chantilly facility in 2026 and holds DEA approval for controlled substance handling.
At a glance
Attribute | Detail |
|---|---|
Founded | 2014 |
Headquarters | Chantilly, Virginia |
Employees | 500-1,000 |
Revenue | $100-250M (estimated) |
Primary capability | Chassis & Safety Systems |
What Granules Pharmaceuticals, Inc. makes
The company operates over 100,000 square feet of manufacturing and R&D space and manufactures modified-release, immediate-release, and extended-release oral dosage forms compliant with Trade Agreements Act standards for U.S. government procurement.
Latest developments
2026-10-07 — Granules India plans ₹2,000 crore investment to drive growth in complex generics, oncology, and peptide CDMO | Hyderabad News - The Times of India (indiatimes.com)
2026-10-06 — Granules Sets $100M Five-Year Peptide CDMO Target (peptideandprotein.com)
2026-06-06 — Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility (pharmatutor.org)
2026-03-11 — Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics (moneycontrol.com)
2026-01-09 — Granules Pharmaceuticals, Inc. Receives FDA Tentative Approval with 180-Day Exclusivity for Generic Amphetamine Extended-Release Tablets | Business News This Week (businessnewsthisweek.com)
2025-12-22 — Granules Pharmaceuticals Receives Tentative FDA ... (medpath.com)
Facilities
Granules Pharmaceuticals, Inc. is headquartered in Chantilly, Virginia. Public sources also reference these locations:
India — pharmatutor.org
Chantilly, Virginia — granulespharma.com
Company details
Granules India, the parent company, announced a $100 million five-year target for peptide contract development and manufacturing services expansion and is pursuing acquisitions to broaden its complex generics portfolio. Granules Pharmaceuticals, Inc. was founded in 2014, has an estimated 500-1,000 employees, and is headquartered in Chantilly, Virginia.
Frequently asked questions
What does Granules Pharmaceuticals, Inc. make?
Granules Pharmaceuticals, Inc. is a U.S. subsidiary of Granules India Limited, headquartered in Chantilly, Virginia, and founded in 2014. The company employs 500–1,000 people and generates an estimated $100–250 million in annual revenue. It manufactures complex oral solid dosage forms including tablets, capsules, powders, and oral solutions for pharmaceutical clients. The firm received FDA Establishment Inspection Report clearance for its Chantilly facility in 2026 and holds DEA approval for controlled substance handling.
Where is Granules Pharmaceuticals, Inc. headquartered?
Granules Pharmaceuticals, Inc. is headquartered in Chantilly, Virginia (3701 Concorde Pkwy, Chantilly, Virginia, 20151-1126).
When was Granules Pharmaceuticals, Inc. founded?
Granules Pharmaceuticals, Inc. was founded in 2014.
How big is Granules Pharmaceuticals, Inc.?
Granules Pharmaceuticals, Inc. has an estimated 500-1,000 employees, with revenue in the $100-250M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
